
    
      Primary IGFD is a term that has been used to describe patients with intrinsic cellular
      defects in GH action. In this protocol, subjects that have completed one year of mecasermin
      treatment on Tercica protocol MS301 (NCT00125164) will be allowed to enroll in this extension
      study. All subjects were planned to receive treatment.

      This is a Phase IIIb open-label, multi-center, parallel dose, extension study conducted in
      approximately 40 centers across the United States.
    
  